Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 113.50p 112.00p 115.00p 113.50p 113.50p 113.50p 1,821 07:52:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -0.3 - 58.29

Verona Pharma Share Discussion Threads

Showing 12676 to 12699 of 12700 messages
Chat Pages: 508  507  506  505  504  503  502  501  500  499  498  497  Older
DateSubjectAuthorDiscuss
17/11/2017
13:23
Thanks for the thoughts timbo..
haff1
17/11/2017
11:01
There must be better prospects than this. I keep looking at Vernalis -every man and his dog are negative.. often a good time to buy.
meijiman
17/11/2017
10:36
>>>>haff1 I think providing they concentrate on the original objective, i.e. to get it approved as a nebulised solution for ER use (and post ER use) and they can generate data so they can make a pharmaco-economic argument that using nebulised RPL554 as rescue medication in ER (and afterwards to reduce readmissions), it should come good in the end. The CF will be nice to have and so will a DPI and MDI formats, but they should concentrate on their knitting IMO.
timbo003
17/11/2017
10:28
would be interesting to hear views of the more expert posters on the prospects for this ? It's looking more and more like a dog. Woof woof.
meijiman
17/11/2017
10:06
timbo. that would suggest we are all stuffed here then?
haff1
16/11/2017
14:05
Heavily manipulated and shorted by those in dark glasses. Easy money. Why rob a Bank when you can steal money this easily
insideryou
16/11/2017
11:38
GSK received approval today in Europe for their triple combo (Trelegy Ellipta) for COPD: https://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/trelegy-ellipta-eu-approval-for-treatment-of-copd/201711160700026797W/
timbo003
16/11/2017
11:24
Meu are recruiting for patients to trial rpl554 2 month study
steven1404
15/11/2017
18:00
Bewise all good?? Really not to sure looking at the share price Shocked and maybe going to see some poor results from current trial.
shakin not stirred
09/11/2017
12:04
Its a shame the share price doesnt reflect this..
haff1
07/11/2017
10:36
All good :)
bewise2
07/11/2017
09:20
Excellent News here. Recruiting ahead of plan is an encouraging sign, it means the clinicians are confident of success.
bonzo
01/11/2017
08:06
Seriously who buys 8 shares? Hmm dip toes in now ahead of results or wait and see...
rathean
27/9/2017
07:28
Certainly looks encouraging!
bonzo
27/9/2017
06:36
It may not be earth shattering news this morning, but it is another box to tick. Circa 10% was delivered by the oral route via the nebuliser, that seems like a mighty efficient nebuliser, I thought he norm for drugs administered via the inhalation route was >20%. I see that they have confirmed a long half life too, so that suggests that if any of the effects are systemic (anti-inflammatory effects?) they will probably have a sustained duration which would be consistent with once or twice a day dosing.
timbo003
08/9/2017
08:27
Yes this is still grosly under priced but still needs that license with a major pharma to rocket. The market for the product is massive...
haff1
08/9/2017
07:43
Now regained my original target of 150 where I had previously sold half my EIS holding. It will be interesting to see if it breaks through the 200 & 300 resistance levels and if it ever regains the 600 level at which I would be a seller.
127tolmers
07/9/2017
22:57
At a closing price of $16.60 on Nasdaq and an exchange rate of $1.31, the Nasdaq price is equivalent to approximately £1.58 per share in the UK (based on 8 ordinary shares per ADS).
lord buffett
07/9/2017
19:02
Up over 40% on Nasdaq
bewise2
07/9/2017
08:01
Good to see some positive movement again. Trial results look very encouraging.
bonzo
07/9/2017
06:56
Presentation slides for today's webcast now available: http://investors.veronapharma.com/static-files/b1220642-7ce6-4b02-9fb2-2358f01d82e5
timbo003
07/9/2017
06:47
>>bewise Indeed I think VRP have previously demonstrated an additive effect with a SAMA, but now they have demonstrated an additive effect with a LAMA (twice a day dosing). A nice clean result and it adds further support for the 6mg dose (rather than a lower dose)
timbo003
07/9/2017
06:31
Rns: excellant news today :)
bewise2
05/9/2017
22:47
PHOWDO on what assumption do you base that . Have you had experience of Stifel as a broker and Nomad before and can you divulge further evidence to your remark. I have no knowledge of them. Cheers
shakin not stirred
Chat Pages: 508  507  506  505  504  503  502  501  500  499  498  497  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171120 19:23:01